Oramed Invests $36.9M in Strategic Partnership with Alpha Tau Medical

Oramed Pharmaceuticals Inc., a leader in oral drug delivery solutions, has announced its strategic investment in Alpha Tau Medical Ltd., a company focusing on alpha-radiation cancer therapy. The investment involves Oramed acquiring approximately 14.1 million shares of Alpha Tau at a price of $2.612 per share through a registered direct offering. This collaboration marks a significant step in merging Oramed’s capital market expertise with Alpha Tau’s innovative cancer treatment technology.

The partnership also includes a three-year service agreement where Oramed will provide strategic guidance and shareholder outreach to Alpha Tau. This move aligns with Oramed's strategy to broaden its presence in the field of therapeutic delivery technologies. An exciting aspect of this collaboration is Oramed’s inclusion in Alpha Tau’s governance with two directors joining Alpha Tau’s Board. This strategic involvement is a testament to Oramed's commitment to supporting Alpha Tau's growth and market strategy.

Oramed’s CEO, Nadav Kidron, expressed enthusiasm about the alliance, highlighting the opportunity to support Alpha Tau’s advanced cancer therapy technology with Oramed’s expertise in capital markets and business development. Kidron emphasized the shared vision of both companies to revolutionize therapeutic delivery, with Oramed focusing on oral drug administration and Alpha Tau on precision radiation therapy. He expressed confidence in Alpha Tau’s technology and leadership and anticipated substantial progress as Alpha Tau continues with its clinical and commercial plans.

Echoing this sentiment, Uzi Sofer, CEO of Alpha Tau, welcomed Oramed as a strategic partner, recognizing the alignment in both companies' missions to transform therapeutic delivery methods. Sofer noted that the investment is timely, given Alpha Tau’s expanding business activities, which include multiple clinical trials in the U.S. and growth in manufacturing capacity. The partnership is expected to foster a productive relationship, enhancing Alpha Tau’s journey towards commercial success.

Oramed Pharmaceuticals is known for its innovative Protein Oral Delivery (POD™) technology, which enhances drug absorption and integrity. With offices in the United States and Israel, Oramed continues to lead in transforming injectable drug delivery into oral formats. Meanwhile, Alpha Tau Medical, established in 2016, is an Israeli company dedicated to developing the Alpha DaRT® technology for treating solid tumors, initially developed by professors from Tel Aviv University.

This collaboration signifies a blend of pioneering technologies in therapeutic delivery, promising advancements in cancer treatment. Both companies stand to benefit from each other’s strengths, paving the way for breakthroughs in medical technology and patient care.